- Home
- PRTA
as 01-17-2025 4:00pm EST
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 643.0M | IPO Year: | N/A |
| Target Price: | $46.50 | AVG Volume (30 days): | 711.1K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.70 - $34.75 | Next Earning Date: | 02-13-2025 |
| Revenue: | $133,350,000 | Revenue Growth: | -5.41% |
| Revenue Growth (this year): | 56.89% | Revenue Growth (next year): | -47.99% |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Business Wire
20 days ago
Prothena Announces Board of Directors Update
Simply Wall St.
25 days ago
We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate
MT Newswires
a month ago
Chardan Initiates Coverage on Prothena With Buy Rating, $40 Price Target
Investor's Business Daily
a month ago
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
Clinical Trials Arena
a month ago
Prothena’s Parkinson’s study fails primary endpoint despite some success
MT Newswires
a month ago
Prothena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint
Business Wire
a month ago
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
Zacks
a month ago
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.